Rivastigmine in moderately severe-to-severe Alzheimer’s disease: Severe Impairment Battery factor analysis

INTRODUCTION: The Severe Impairment Battery (SIB) is validated for assessing cognition in patients with severe dementia. The current analysis aimed to further investigate the cognitive efficacy of rivastigmine capsules, as assessed by SIB factor scores, in patients with moderately severe-to-severe A...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferris, Steven, Karantzoulis, Stella, Somogyi, Monique, Meng, Xiangyi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978681/
https://www.ncbi.nlm.nih.gov/pubmed/24351447
http://dx.doi.org/10.1186/alzrt229

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978681/
https://www.ncbi.nlm.nih.gov/pubmed/24351447
http://dx.doi.org/10.1186/alzrt229

Ejemplares similares